TG Therapeutics Raises Revenue Guidance on Strong BRIUMVI Performance
Event summary
- Q2 2026 revenue hit $240.3M, with BRIUMVI U.S. net product revenue at $227.7M.
- Full-year 2026 revenue guidance raised to ~$950M, up from prior estimates.
- Positive Phase 3 ENHANCE trial results support a simplified BRIUMVI dosing regimen.
- Subcutaneous BRIUMVI Phase 1 data shows >60% bioavailability relative to IV administration.
The big picture
TG Therapeutics is solidifying BRIUMVI as a cornerstone in treating relapsing multiple sclerosis (RMS), with revenue growth outpacing expectations. The company's strategic focus on expanding indications—including myasthenia gravis and schizophrenia—and advancing subcutaneous formulations positions it to capture broader market opportunities. However, execution risks remain, particularly around clinical trial timelines and manufacturing scalability.
What we're watching
- Commercial Momentum
- Whether TG Therapeutics can sustain BRIUMVI's rapid revenue growth amid increasing competition in the MS treatment space.
- Pipeline Progress
- The pace at which subcutaneous BRIUMVI and other pipeline candidates advance through clinical trials, particularly given the anticipated Phase 3 data by year-end 2026 or early 2027.
- Operational Efficiency
- How TG Therapeutics manages rising R&D and SG&A expenses while maintaining profitability, especially with projected operating expenses of $350–400M for 2026.
Related topics